TYLENOL WITH NAPROXEN Drug Patent Profile
Which patents cover Tylenol With Naproxen, and when can generic versions of Tylenol With Naproxen launch?
Tylenol With Naproxen is a drug marketed by Kenvue Brands and is included in one NDA.
The generic ingredient in TYLENOL WITH NAPROXEN is acetaminophen; naproxen sodium. Additional details are available on the acetaminophen; naproxen sodium profile page.
US Patents and Regulatory Information for TYLENOL WITH NAPROXEN
TYLENOL WITH NAPROXEN is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TYLENOL WITH NAPROXEN is ⤷ Start Trial.
This potential generic entry date is based on NEW PRODUCT.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kenvue Brands | TYLENOL WITH NAPROXEN | acetaminophen; naproxen sodium | TABLET;ORAL | 219962-001 | Jul 24, 2026 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
